Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, Zhu H, Wang CY, Carpenter AB, Friedman H, Friedman AH, Keir ST, He J, He Y, McLendon RE, Herndon JE 2nd, Yan H, Bigner DD.

Oncotarget. 2014 Mar 30;5(6):1515-25.

2.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0. Epub 2015 Mar 18.

3.

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.

Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94. Epub 2014 Aug 1.

4.

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y.

Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.

5.

Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.

Tang C, Zhang ZY, Chen LC, Sun Z, Zhang Y, Qin Z, Yao Y, Zhou LF.

J Neurooncol. 2016 Feb;126(3):499-507. doi: 10.1007/s11060-015-1989-5. Epub 2015 Nov 19.

PMID:
26586262
6.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

7.

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H.

Oncotarget. 2012 Jul;3(7):709-22.

8.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

9.

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.

Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25.

PMID:
19554337
10.

TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.

Gao K, Li G, Qu Y, Wang M, Cui B, Ji M, Shi B, Hou P.

Oncotarget. 2016 Feb 23;7(8):8712-25. doi: 10.18632/oncotarget.6007.

11.

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB.

N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.

12.

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.

Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y, Rahimian A, Finocchiaro G, Houlston RS, Hoang-Xuan K, Idbaih A, Delattre JY, Mokhtari K, Sanson M.

Br J Cancer. 2014 Nov 11;111(10):2024-32. doi: 10.1038/bjc.2014.538. Epub 2014 Oct 14.

13.

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.

Reich TR, Switzeny OJ, Renovanz M, Sommer C, Kaina B, Christmann M, Tomicic MT.

Oncotarget. 2017 Feb 28;8(9):15071-15084. doi: 10.18632/oncotarget.14748.

14.

Combination genetic signature stratifies lower-grade gliomas better than histological grade.

Chan AK, Yao Y, Zhang Z, Shi Z, Chen L, Chung NY, Liu JS, Li KK, Chan DT, Poon WS, Wang Y, Zhou L, Ng HK.

Oncotarget. 2015 Aug 28;6(25):20885-901.

15.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
16.

Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.

Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project.

Neuro Oncol. 2016 Aug;18(8):1099-108. doi: 10.1093/neuonc/now021. Epub 2016 Mar 7.

17.

Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.

Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A.

J Natl Cancer Inst. 2012 Oct 3;104(19):1458-69. doi: 10.1093/jnci/djs357. Epub 2012 Sep 3.

18.
19.

IDH2 mutation in gliomas including novel mutation.

Koh J, Cho H, Kim H, Kim SI, Yun S, Park CK, Lee SH, Choi SH, Park SH.

Neuropathology. 2015 Jun;35(3):236-44. doi: 10.1111/neup.12187. Epub 2014 Dec 12.

PMID:
25495392
20.

Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.

Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S.

Brain Tumor Pathol. 2012 Oct;29(4):183-91. doi: 10.1007/s10014-012-0113-1. Epub 2012 Jul 13.

PMID:
22790483

Supplemental Content

Support Center